[Reinfection with Schistosoma haematobium and mansoni despite repeated praziquantel office treatment in Niger, Mali].
The dynamics of reinfection by Schistosoma haematobium and Schistosoma mansoni after repeated treatment with praziquantel (40 mg/kg body weight, single dose) was studied in a cohort of schoolchildren living in an endemic area. A total of 214 urine and 220 stool samples were collected and examined at three different times, i.e., February 1989, July 1989 and February 1990. Mass chemotherapy was administered at the beginning of study (February 89). Treatment was repeated in children with positive tests at each subsequent sampling. Prevalence rates were 55.1 p. 100, 3.7 p. 100, and 35.0 p. 100 for Schistosoma haematobium and 62.7 p. 100, 46.3 p. 100 and 73.1 p. 100 for Schistosoma mansoni in February 1989, July 1989 and February 1990 respectively (p < 0.001). From July 1989 to February 1990, reinfection was observed in 84.5 p. 100 of children by Schistosoma haematobium versus 57.8 p. 100 by Schistosoma mansoni. The risk of reinfection by Schistosoma haematobium was higher in children between the ages of 7 and 10 years than in children between the ages of 11 and 15 years (p < 0.001), The incidence of intense Schistosoma haematobium egg excretion rose from 0 p. 100 in July 1989 to 6.0 p. 100 in February 1990. The incidence of intense Schistosoma mansoni excretion in February 1990 was 4.5 p. 100. The reinfection rate at 7 months was over 50 p. 100 for both parasite species despite repeated treatment. This finding demonstrates that additional measures such as proper sanitation and vector control are needed to control human schistosomiasis in irrigated rice paddies.
Dabo
A
A
Service de Biologie Moléculaire de l'Université d'Heidelberg, Allemagne. adabo@mrtcbko.malinet.ml
Doucoure
B
B
Koita
O
O
Diallo
M
M
Kouriba
B
B
Klinkert
M Q
MQ
Doumbia
S
S
Doumbo
O
O
D000293:Adolescent; D017677:Age Distribution; D000383:Agriculture; D000871:Anthelmintics / Q000627:therapeutic use*; D002648:Child; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D008302:Mali / Q000453:epidemiology; D009819:Office Visits; D012275:Oryza; D011223:Praziquantel / Q000627:therapeutic use*; D015995:Prevalence; D012008:Recurrence; D012553:Schistosomiasis haematobia / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology* / Q000469:parasitology; D012555:Schistosomiasis mansoni / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology* / Q000469:parasitology; D012621:Seasons; D013334:Students / Q000706:statistics & numerical data; D017211:Treatment Failure; D014867:Water / Q000469:parasitology
D000871:Anthelmintics; D014867:Water; D011223:Praziquantel